Zyla Life Sciences
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8M | $30.4M | $26.1M | $2.7M | $22.8M | $1.9M |
| Operating income | −$8.1M | −$57.6M | −$68.2M | −$81.0M | −$52.2M | −$37.1M |
| Net income | $107.2M | −$95.5M | −$69.4M | −$90.6M | −$57.9M | — |
| Total assets | $59.9M | $61.9M | $119.9M | $114.9M | $172.4M | $60.6M |
| Total liabilities | — | — | $159.2M | $109.5M | $83.2M | $16.3M |
| Equity | −$118.0M | −$111.4M | −$39.4M | $5.3M | $89.2M | $44.3M |
| EPS (diluted) | — | — | $-1.02 | — | — | — |
| Shares out. | 9.4M | 47.0M | 25.2M | 25.1M | 17.3M | 17.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- −457.5%
- Net margin
- 6041.7%
- Return on equity
- −90.9%
- Return on assets
- 179.0%
- Return on capital (ROCE)
- −36.3%
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $-12.60
- Revenue growth (YoY)
- −94.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Accruals / assets
- 177.6%high accruals
- Piotroski F-Score
- 4/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 1 good- Negative shareholder equity
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Revenue declined year-over-year
- High accruals — earnings-quality risk
- Positive operating cash flow
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 15, 2019
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
FDA-approved drugs
openFDA · most recent- INDOCINJun 10, 1965
Material events
SEC Form 8-K · most recent- Regulation FD disclosureMay 20, 2020
- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder voteMay 20, 2020
- Other material eventMay 15, 2020
- Results of operations · Other material eventMay 15, 2020
- Director / officer change · Other material eventApr 13, 2020
- Results of operations · Other material eventMar 27, 2020
- Entered a material agreement · Results of operationsMar 17, 2020
- Entered a material agreement · Other material eventJan 28, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AJan 29, 2021
- 15-12BJun 1, 2020
- 4FORM 4 SUBMISSIONMay 22, 2020
- SC 13D/AMay 22, 2020
- 4May 21, 2020
- 4May 21, 2020
- 4May 21, 2020
- 4May 21, 2020
- 4May 21, 2020
- 4May 21, 2020
- 4May 21, 2020
- 4May 21, 2020
- 8-KFORM 8-KMay 20, 2020
- 8-KFORM 8-KMay 20, 2020
- 25May 20, 2020